Ozempic promotes weight loss by mimicking the GLP-1 hormone the body naturally produces after eating, so users feel full for ...

The American Diabetes Association (ADA) urged healthcare providers against prescribing non-FDA approved compounded GLP-1 and ...

While B-ALL is the most common childhood cancer and one of the most treatable, some patients face grim outcomes after they ...

If you're in a relationship that faces struggles with weight and are considering GLP-1 medications like Ozempic, consider ...

Researchers have developed and are testing a small, implanted gastric balloon that people can inflate or deflate to feel full ...

Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) ("Amylyx" or the "Company") today announced the design of its pivotal Phase 3 LUCIDITY clinical trial for avexitide, an investigational, first-in-class ...

Target RWE, a leader in real-world evidence solutions in liver disease, presented important research on the use of glucagon-like peptide-1 receptor agonists (GLP-1 RA) among patients with metabolic ...

Amylin analogs present a strong alternative or complement to GLP-1 receptor agonists, potentially eliciting higher-quality ...

The Danish pharma group is pledging $285 million in upfront and milestone payments for the lead GLP-1 asset in the partnership ... and potentially reduce the cost of therapy.

For employers wanting to dip a toe into the GLP-1 medications pool, utilization management is recommended to control costs.

Leptin by itself doesn't hold promise for weight loss — but a new mouse study suggests it could work in combination with ...

Use of the GLP-1 agonist was associated ... AbbVie has finally claimed FDA approval for its advanced Parkinson's disease therapy Vyalev, 18 months after the US regulator turned it down with ...